{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:58:28Z","timestamp":1791280708892,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1684\/bdc.2013.1738","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:58:43Z","timestamp":1565726323000},"page":"473-484","source":"Crossref","is-referenced-by-count":19,"title":["Observance des m\u00e9dicaments anticanc\u00e9reux"],"prefix":"10.1016","volume":"100","author":[{"given":"Fabien","family":"Despas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2013.1738_bib0005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1738_bib0010","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/1097-0142(19910215)67:4<945::AID-CNCR2820670415>3.0.CO;2-R","article-title":"Predictors of physician nonadherence to chemotherapy regimens","volume":"67","author":"Schleifer","year":"1991","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1738_bib0015","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archinte.1990.00390190143023","article-title":"Compliance declines between clinic visits","volume":"150","author":"Cramer","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1684\/bdc.2013.1738_bib0020","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdn646","article-title":"Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer","volume":"20","author":"Ziller","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0030","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.22485","article-title":"Early discontinuation of tamoxifen: a lesson for oncologists","volume":"109","author":"Barron","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1738_bib0035","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","volume":"28","author":"Hershman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0040","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2010.33.3179","article-title":"Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer","volume":"29","author":"Neugut","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/COC.0b013e3182436ec1","article-title":"Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women","volume":"36","author":"Weaver","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2006.10.1022","article-title":"Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer","volume":"26","author":"Owusu","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0055","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1200\/JCO.2004.11.064","article-title":"Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer","volume":"22","author":"Fink","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0060","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.2002.08.137","article-title":"Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer","volume":"20","author":"Silliman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0065","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2013.1738_bib0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1684\/bdc.2013.1738_bib0075","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2013.1738_bib0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00019053-200725040-00002","article-title":"Measuring patient-reported outcomes in solid organ transplant recipients: an overview of instruments developed to date","volume":"25","author":"Cleemput","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1684\/bdc.2013.1738_bib0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1634\/theoncologist.9-3-259","article-title":"Optimizing treatment of chronic myeloid leukemia: a rational approach","volume":"9","author":"Stone","year":"2004","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2013.1738_bib0090","first-page":"1407","article-title":"Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study","volume":"31","author":"Mazzeo","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1684\/bdc.2013.1738_bib0095","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00277-011-1359-0","article-title":"Good adherence to imatinib therapy among patients with chronic myeloid leukemia \u2013 a single-center observational study","volume":"91","author":"Jonsson","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1684\/bdc.2013.1738_bib0100","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group","volume":"30","author":"Bhatia","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0105","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1200\/JCO.2009.22.2802","article-title":"Review of adherence-related issues in adolescents and young adults with cancer","volume":"28","author":"Butow","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0022-3476(05)80256-2","article-title":"Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment","volume":"120","author":"Festa","year":"1992","journal-title":"J Pediatr"},{"key":"10.1684\/bdc.2013.1738_bib0115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ejon.2011.10.002","article-title":"A review on adherence management in patients on oral cancer therapies","volume":"16","author":"Wood","year":"2012","journal-title":"Eur J Oncol Nurs"},{"key":"10.1684\/bdc.2013.1738_bib0120","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/annonc\/mds133","article-title":"Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (adherence companion study 60104 for CALGB 49907)","volume":"23","author":"Ruddy","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0125","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1200\/JCO.2009.26.4671","article-title":"Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104","volume":"28","author":"Partridge","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0130","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00520-010-0927-5","article-title":"Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care","volume":"19","author":"Simons","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2013.1738_bib0135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1078155211436022","article-title":"Capecitabine non-adherence: exploration of magnitude, nature and contributing factors","volume":"18","author":"Bhattacharya","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"10.1684\/bdc.2013.1738_bib0140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ajh.21968","article-title":"Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease","volume":"86","author":"Candrilli","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1684\/bdc.2013.1738_bib0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2012.070755","article-title":"Impact of dose intensity on the outcomes of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy of chronic lymphocytic leukemia","volume":"98","author":"Bouvet","year":"2013","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2013.1738_bib0150","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00228-012-1290-x","article-title":"Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden","volume":"68","author":"Grundmark","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1684\/bdc.2013.1738_bib0155","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1471-2407-11-284","article-title":"The use of erlotinib in daily practice: a study on adherence and patients\u2019 experiences","volume":"11","author":"Timmers","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1684\/bdc.2013.1738_bib0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1188\/10.CJON.223-233","article-title":"Lapatinib side-effect management","volume":"14","author":"Frankel","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"10.1684\/bdc.2013.1738_bib0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1179\/joc.2010.22.3.205","article-title":"Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions","volume":"22","author":"Welker","year":"2010","journal-title":"J Chemother"},{"key":"10.1684\/bdc.2013.1738_bib0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnci\/djr511","article-title":"Targeted therapies for renal cell carcinoma: review of adverse event management strategies","volume":"104","author":"Eisen","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2013.1738_bib0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1738_bib0180","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0185","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/cncr.22939","article-title":"Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy","volume":"110","author":"Shayne","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1738_bib0190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","article-title":"Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy","volume":"87","author":"Pettengell","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1684\/bdc.2013.1738_bib0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","article-title":"Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma","volume":"77","author":"Wildiers","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1684\/bdc.2013.1738_bib0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1684\/bdc.2013.1738_bib0205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1756-9966-28-116","article-title":"Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma","volume":"28","author":"Terada","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1684\/bdc.2013.1738_bib0210","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","article-title":"Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma","volume":"89","author":"Hirakawa","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1684\/bdc.2013.1738_bib0215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM198101013040103","article-title":"Dose-response effect of adjuvant chemotherapy in breast cancer","volume":"304","author":"Bonadonna","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1738_bib0220","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1738_bib0225","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2005.05.059","article-title":"Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial","volume":"23","author":"Bonneterre","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0230","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S0895-4356(01)00450-4","article-title":"Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence","volume":"54","author":"Wagner","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1684\/bdc.2013.1738_bib0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00126334-200306010-00022","article-title":"Assessment of adherence to triple antiretroviral treatment including indinavir: role of the determination of plasma levels of indinavir","volume":"33","author":"Alcoba","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1684\/bdc.2013.1738_bib0240","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1037\/a0016940","article-title":"The impact of cognitive function on medication management: three studies","volume":"29","author":"Stilley","year":"2010","journal-title":"Health Psychol"},{"key":"10.1684\/bdc.2013.1738_bib0245","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1200\/JCO.2009.22.0038","article-title":"Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study","volume":"27","author":"Loberiza","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0250","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.bbmt.2007.09.006","article-title":"Disparity in survival outcome after hematopoietic stem cell transplantation for hematologic malignancies according to area of primary residence","volume":"13","author":"Rao","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1684\/bdc.2013.1738_bib0255","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JOP.2011.000274","article-title":"Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center","volume":"8","author":"Nguyen","year":"2012","journal-title":"J Oncol Pract"},{"key":"10.1684\/bdc.2013.1738_bib0260","first-page":"267","article-title":"Therapeutic education in oncology: involving patient in the management of cancer","volume":"94","author":"Perol","year":"2007","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2013.1738_bib0265","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1200\/JCO.2006.07.0474","article-title":"Models for delivering survivorship care","volume":"24","author":"Oeffinger","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1738_bib0270","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ijnurstu.2011.01.008","article-title":"Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: the Ambulatory Medical Assistance (AMA) experience","volume":"48","author":"Compaci","year":"2011","journal-title":"Int J Nurs Stud"},{"key":"10.1684\/bdc.2013.1738_bib0275","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-005-0925-6","article-title":"\u201cMedicamentation\u201d of society, non-diseases and non-medications: a point of view from social pharmacology","volume":"61","author":"Mbongue","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1684\/bdc.2013.1738_bib0280","first-page":"420","article-title":"Social pharmacology: a new topic in clinical pharmacology","volume":"57","author":"Montastruc","year":"2002","journal-title":"Therapie"},{"key":"10.1684\/bdc.2013.1738_bib0285","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1684\/bdc.2013.1738_bib0290","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00002030-200201250-00017","article-title":"Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome","volume":"16","author":"Walsh","year":"2002","journal-title":"AIDS"},{"key":"10.1684\/bdc.2013.1738_bib0295","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115303386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115303386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T17:14:33Z","timestamp":1610817273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115303386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0007455115303386"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2013.1738","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}